Adriamycin-based chemotherapy

Phase 2Small molecule

SSun Yat-sen University

Adriamycin-based chemotherapy is one of 6 small molecule programs targeting Sintilimab. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

SintilimabRecruiting

SintilimabPhase 2

Recruiting

Competition

Competitive Landscape

7 competitors in Sintilimab

#DrugCompanyPhaseTrials

Tyvyt

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

12 2

Lenvima

Eisai

Phase 3

2 3

Experimental Drug

MMedesis Pharma SA

Phase 3

1 4

Sintilimab Plus Chemotherapy

FFudan University

Phase 2

1 5

Adriamycin-based chemotherapy

SSun Yat-sen University

Phase 2

1 6

Sintilimab Combined With Anlotinib

ZZhejiang Cancer Hospital

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Sintilimab1 trial

Adriamycin and Ifosfamide Combined With Sintilimab

Recruiting·SSun Yat-sen University·Phase 2·NCT04589754·176 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Adriamycin-based chemotherapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Adriamycin-based chemotherapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Adriamycin-based chemotherapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sun Yat-sen University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSun Yat-sen University

Adriamycin-based chemotherapy

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Sintilimab1 trial

References

Drug Info

Quick Facts

Related News